Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy
Cochrane Database Syst Rev
Antibodies to the red cell Rhesus D (RhD) antigen can be produced during pregnancy in a RhD-negative mother carrying a RhDpositive fetus, in particular following feto-maternal haemorrhage at birth or following any procedure that may cause feto-maternal haemorrhage. While the first baby is usually not harmed, these antibodies may cause haemolytic disease of the fetus/newborn (HDFN) in subsequent RhD-positive babies. RhD incompatibility is a major cause of HDFN. To reduce the risk of HDFN, anti-D is given to RhD-negative mothers at 28 or 30 weeks of pregnancy and within 72 hours of potential maternal exposure to fetal red cells. Anit-D is currently available in both intramuscular (IM) and intravenous (IV) preparations.
Antibodies , Pregnancy , Feto-maternal haemorrhage , Disease , Research Subject Categories::MEDICINE::Surgery::Obstetrics and women's diseases
Okwundu CI, Afolabi BB. Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD007885. doi: 10.1002/14651858.CD007885.pub2. Review. PubMed PMID: 23440818.